10-Q: Anebulo Shifts Focus to Pediatric Cannabis Toxicity, Explores Going Private

Anebulo Pharmaceuticals reports a reduced net loss for Q1 2026, pivots its lead drug development to pediatric cannabis toxicity, and is actively reviewing strategic alternatives including a proposed going-private transaction.

Summary

• Net loss for the three months ended September 30, 2025, was $2.16 million, a slight improvement from $2.20 million in the prior year period.
• Cash and cash equivalents stood at $10.35 million as of September 30, 2025, down from $11.63 million on June 30, 2025.
• The company is prioritizing the development of an intravenous (IV) formulation of selonabant for pediatric unintentional cannabis poisoning, shifting focus from the adult oral ACI treatment.
• A single ascending dose (SAD) study of IV selonabant in healthy adults was initiated in Q3 calendar 2025 and is ongoing.
• Anebulo received a Year 2 grant award of approximately $1.0 million from the National Institute on Drug Abuse (NIDA) on September 2, 2025, to support IV selonabant development.
• The Board approved a proposed going private transaction, including a reverse stock split (1-for-2,500 to 1-for-7,500) to delist from Nasdaq and deregister from the SEC, but is now reviewing all strategic alternatives due to inbound interest.
• Professional and consultant fees increased by $0.4 million, primarily due to expenses recognized in connection with the potential going private transaction.
• Research and development expenses decreased by $0.5 million, mainly due to the timing of clinical studies and contract manufacturing.
• The company expects its current cash and available funding under the Loan Agreement to fund operations for at least the next 12 months.

Sentiment

Score: 4

Explanation: The company shows a slight improvement in net loss and cash burn, and its strategic pivot to pediatric IV selonabant is a positive development addressing an unmet need with FDA support. However, the proposed going-private transaction introduces significant uncertainty and potential negative impacts for public shareholders, including delisting and illiquidity. The reliance on future capital raises and the impact of government shutdowns also weigh on the sentiment.

Positives

• Net loss decreased to $2.16 million for the three months ended September 30, 2025, from $2.20 million in the prior year period.
• Net loss per share improved to $(0.05) from $(0.08) year-over-year.
• Net cash used in operating activities decreased to $1.27 million from $1.69 million in the prior year period.
• Strategic shift to IV selonabant for pediatric cannabis toxicity addresses an acknowledged unmet medical need and has FDA support for close collaboration.
• Received a $1.0 million Year 2 grant from NIDA for IV selonabant development, indicating external validation and funding support.
• Interest income increased to $109,616 from $26,006 due to an overall increase in average cash and cash equivalents.
• Patent protection for selonabant is robust with three issued US patents and rights to additional applications.

Negatives

• Cash and cash equivalents decreased to $10.35 million as of September 30, 2025, from $11.63 million on June 30, 2025.
• Accumulated deficit increased to $76.05 million as of September 30, 2025.
• Grant income significantly decreased to $9,825 from $245,362 in the prior year period due to timing of expenditures for reimbursable grant-related activities.
• General and administrative expenses increased by $0.4 million, primarily due to costs associated with the potential going private transaction.
• The Loan Agreement's maximum advance was reduced from $10 million to $3 million, limiting potential debt funding.
• The proposed going private transaction and delisting from Nasdaq could lead to significantly less information for investors and increased illiquidity of common stock.

Risks

• Inability to generate sufficient revenue or source additional funding, potentially leading to delays, scaling back, or elimination of product development.
• Substantial dilution for existing stockholders if additional capital is raised through equity or equity-linked securities, including the issuance of shares under the Loan Agreement.
• Uncertainty and potential adverse effects of the proposed going private transaction, including delisting from Nasdaq and deregistration from the SEC, which would reduce public information and increase stock illiquidity.
• Impact of U.S. federal government shutdowns on the FDA, SEC, NIH, and USPTO, potentially delaying regulatory approvals, grant funding, and access to capital markets.
• Dependence on timely interactions with the FDA for regulatory submissions and clinical trial oversight.
• Restrictive provisions in government grants that could require repayment if covenants are violated.
• Uncertainty regarding how a new administration might modify FDA policies, potentially creating a more challenging regulatory environment.
• Lack of experience in obtaining regulatory approval and commercializing drug products independently.
• Potential for unanticipated clinical trial delays, poor data, or changes in the regulatory and competitive landscape.

Future Outlook

The company expects to continue incurring significant operating losses and negative cash flows as it advances clinical development. It anticipates needing to raise additional funding beyond its current cash and available loan facility to meet development and commercialization objectives. The strategic focus is now on the intravenous selonabant formulation for pediatric cannabis toxicity, with an ongoing SAD study in healthy adults. The Board is reviewing all strategic alternatives, including a proposed going private transaction and potential asset sale or merger, with a further announcement expected by year-end.

Management Comments

• We expect that our cash and cash equivalents, along with available funding under the Loan Agreement, will be sufficient to fund our operating expenses and capital expenditure requirements through at least 12 months from the issuance date of the financial statements.
• The FDA acknowledged the unmet need for a treatment for children exposed to cannabis toxicity, and proposed a close, ongoing collaboration to efficiently advance the selonabant program for the pediatric indication.
• We believe the number of cannabis-related emergency department visits and health problems associated with unintentional cannabis poisoning and ACI will continue to increase substantially as more states pass laws legalizing cannabis for medical and recreational use.
• Our belief is that the path to approval for an oral treatment for adult ACI may be facilitated by an initial approval for intravenous treatment of unintentional cannabis poisoning in the pediatric population.
• With this unprecedented change in cannabis regulation, Anebulo is uniquely positioned to become a provider of a rapid and clinically impactful solution for Emergency Departments to treat pediatric patients suffering from unintentional cannabis poisoning.
• The Board expects to make a further announcement regarding the strategic alternatives review process by the end of this year.

Industry Context

The U.S. cannabis market is experiencing significant growth and regulatory changes, including the potential rescheduling of marijuana from Schedule I to Schedule III. This trend is leading to a dramatic increase in cannabis-related emergency department visits, particularly unintentional poisonings in children. Anebulo's strategic pivot to develop an IV treatment for pediatric cannabis toxicity positions it to address a growing, unmet medical need in a vulnerable population, potentially becoming a first-mover in a market with no approved specific antidotes. The company believes this pediatric focus could also accelerate the path to approval for adult ACI treatments.

Corporate Governance

Related Party Transactions

• The company entered into a securities purchase agreement in December 2024 with 22NW Fund, LP, a greater than 5% stockholder controlled by Aron English, a director.
• The Loan Agreement (modified February 10, 2025) is with 22NW Fund, LP (Aron R. English and Nathaniel Calloway are directors) and JFL Capital Management LLC (Joseph F. Lawler, founder and director).
• The company leases its principal executive office space under a sublease with a related party for approximately $400 per month.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future capital raises. The proposed going private transaction and delisting would lead to reduced liquidity and transparency, potentially decreasing share value. The ongoing strategic review introduces uncertainty.
• Employees: Stock-based compensation remains a component of remuneration, aligning interests with company performance.
• Customers (future): The strategic pivot to pediatric IV selonabant aims to address a critical unmet medical need, potentially providing a life-saving treatment.
• Creditors: The Loan Agreement provides a limited source of debt funding, but the company's ongoing losses indicate continued reliance on external financing.
• Regulatory Authorities (FDA, NIDA): The company is actively collaborating with the FDA on the pediatric indication and has secured NIDA grant funding, indicating positive engagement.

Next Steps

• Continue the single ascending dose (SAD) study of IV selonabant in healthy adults.
• Review all strategic alternatives, including the proposed going private transaction, alternative going private transactions, a sale of assets, and/or a merger transaction.
• Make a further announcement regarding the strategic alternatives review process by the end of this year.
• Seek additional funding through equity, debt, or collaboration agreements to support future operations and development.
• Address SEC comments to the proxy statement for the Reverse Stock Split, once government operations allow.

Key Dates

Recommendation

The proposed going-private transaction, including a reverse stock split and delisting from Nasdaq, introduces significant uncertainty and a high probability of reduced liquidity and transparency for public shareholders. While the strategic pivot to pediatric IV selonabant is a positive development, the immediate impact of the going-private plan is highly detrimental to public investors. The company explicitly states that delisting would lead to 'significantly less information regarding our company available to stockholders and potential investors' and 'increased illiquidity would make trading in shares of our common stock more difficult, which could cause the value of our common stock to decrease.' Given these explicit risks to public shareholders and the ongoing strategic review that could lead to various outcomes, including a sale at a loss, a seasoned investor would likely recommend selling to avoid the potential illiquidity and value erosion associated with a delisting and deregistration.

Keywords

Anebulo Pharmaceuticals, ANEB, selonabant, cannabis toxicity, acute cannabinoid intoxication, ACI, pediatric cannabis poisoning, IV selonabant, clinical stage pharmaceutical, drug development, SEC filing, 10-Q, going private, reverse stock split, Nasdaq delisting, NIDA grant, biotechnology, pharmaceuticals